In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Primer On FDA’s "Breakthrough Therapy" Program

Executive Summary

A look at the genesis of the US expedited regulatory pathway for drugs and biologics, its benefits, and how the program is working today.


Related Content

Should You Request "Breakthrough" Status? Sponsors, FDA Give Their Advice
FDA Offers Clues, But No Clear Standards, On "Breakthrough"-Worthiness
FDA Offers Clues, But No Clear Standards, On "Breakthrough"-Worthiness
Beyond "Breakthrough": FDA, Industry See Benefits For Drugs Outside Expedited Pathway
“Breakthrough Therapy” Development Speed May Be Tempered By Manufacturing Hurdles
Industry Wants A Breakthrough Therapy, Even Without All The Standards
FDA “Breakthrough” Designation Bill Revives Debate About Legislating Flexibility
Expedited Approval Pathway Concept Draws Strong Support But Different Proposals





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts